
MOLTENI LAURA
Pubblicazioni
Persico, A., Molteni, L., Mantecca, P., Kravicz, M., Bragato, C. (2025). Transgenic zebrafish embryos to evaluate the in vivo effects of different liposome-paclitaxel nanocarrier system. SCIENTIFIC REPORTS, 15(1) [10.1038/s41598-025-00258-1]. Dettaglio
Fermi, S., Malacrida, A., Molteni, L., Miloso, M., Cavaletti, G., Nicolini, G. (2025). Histone Deacetylase 6 Inhibitors: Mitigators Of Chemotherapy Induced Peripheral Neuropathy Via The NMNAT2/SARM1 Pathway Modulation. Intervento presentato a: 2025 PNS Annual Meeting, Edinburgh, Scotland. Dettaglio
Meanti, R., Bresciani, E., Rizzi, L., Molteni, L., Coco, S., Omeljaniuk, R., et al. (2025). Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases. BIOMÉDECINE & PHARMACOTHÉRAPIE, 186(May 2025) [10.1016/j.biopha.2025.118044]. Dettaglio
Fermi, S., Malacrida, A., Molteni, L., Tarasiuk, O., Miloso, M., Cavaletti, G., et al. (2024). Evaluation of Histone Deacetylase 6 inhibitors as possible neuroprotectors against Paclitaxel-induced peripheral neurotoxicity. In Abstracts of the Fourteenth Annual Meeting of the Associazione italiana per lo studio del Sistema Nervoso Periferico (ASNP), 30 May – 1 June 2024, Trieste, Italy. Dettaglio
Meanti, R., Rizzi, L., Bresciani, E., Licata, M., Molteni, L., Omeljaniuk, R., et al. (2024). Selected Growth Hormone Secretagogues (GHS) as disease modifiers in an in vitro model of Amyotrophic Lateral Sclerosis: a proof-of-concept study. Intervento presentato a: 9th European Congress of Pharmacology (EPHAR 2024), Atene, Grecia. Dettaglio